肉苁蓉苯乙醇苷类成分对BSA诱导的肝纤维化大鼠转化生长因子β1表达的影响

doi:10.3969/j.issn.1004-616x.2015.06.001

Abstract

Abstract:

OBJECTIVE: To observe the effects of cistanche phenylethanoid glycosides(CPhGs) on TGF-β1 expression of rats with hepatic fibrosis induced by bovine serum albumin(BSA). METHODS: Seventy-five SD rats were randomly divided into six groups:Normal(distilled water-treated),model(BSA-treated),positive drug(BSA-treated+ compound Biejia Ruangan tablets(BJRG,600 mg/kg),and BSA-treated+CPhGs(125,250,500 mg/kg) groups. BSAtreated+CPhGs(125,250,500 mg/kg) groups consisted of 13 rats in each group,and other various group had 12 rats in each group. Using intravenously injected BSA-induced rat liver fibrosis model,rats were fed with different therapeutic drugs for 12 weeks. After the experiment serum and liver tissues of rats were collected. Measurements of serum enzymes,liver fibrosis markers,serum TGF-β1 concentration,Masson staining to show the histopathological changes and the expression of TGF-β1 were recorded. RESULTS: Compared with model group,except for ALB and the low dose group TB and DB,various dose CPhGs groups(125,250,and 500 mg/kg) could significantly lower liver enzymes in serum(P<0.05),liver fibrosis markers(P<0.05),and TGF-β1 content(P<0.01). Moreover,Masson staining showed BSA-treated+CPhGs(125,250,500 mg/kg) groups could alleviate the degree of liver fibrosis,which was significantly lower than the model group(P<0.01). The expression of TGF-β1 protein in liver tissue of different dose groups were also inhibited significantly(P<0.05 or P<0.01). CONCLUSION: CPhGs demonstrated protective effects on hepatic fibrosis induced by BSA in rats,and one of mechanisms maybe the inhibited expression of TGF-β1 in hepatic fibrosis tissue.

Key words: cistanche, phenylethanoid glycosides, liver fibrosis, bovine serum albumin, transforming growth factor-β1

CLC Number:

R285.5

YOU Shuping, ZHAO Jun, MUKARAM Tudimat, MA Long, ZHANG Shilei, LIU Tao. The effects of cistanche phenylethanoid glycosides on TGF-β1 expression of rats with hepatic fibrosis induced by BSA[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(6): 409-414.

References

[1] Cohen-Naftaly M,Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease[J]. Therap Adv Gastroenterol,2011,4(6):391-417.
[2] Puche JE,Saiman Y,Friedman SL. Hepatic stellate cells and liver fibrosis[J]. Compr Physiol,2013,3(4):1473-1492.
[3] Hernandez-Gea V,Friedman SL. Pathogenesis of liver fibrosis[J]. Annu Rev Pathol,2011,6(7):425-456.
[4] Kostadinova R,Montagner A,Gouranton E,et al. GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation[J]. Cell Biol Sci,2012,2(1):34-50.
[5] Sohrabpour AA,Mohamadnejad M,Malekzadeh R. Review article:the reversibility of cirrhosis[J]. Aliment Pharmacol Ther,2012,36(9):824-832.
[6] 李媛,宋媛媛,张洪泉.肉苁蓉的化学成分及药理作用研究进展[J].中国野生植物资源,2010,29(1):7-12.
[7] 宋鹏,屠鹏飞.中药肉苁蓉质量控制及评价的研究进展[J].北方药学,2011,8(2):61-62.
[8] 屠鹏飞,姜勇,郭玉海.肉苁蓉研究及其产业发展[J].中国药学杂志,2011,46(12):882-888.
[9] 陈海燕,郝彩琴,郭鸿雁.肉苁蓉药用资源开发与应用研究进展[J].价值工程,2012,31(3):303-305.
[10] 赵微,潘英妮.肉苁蓉苯乙醇苷类成分药理作用研究进展[J].亚太传统医药,2013,9(5):77-79.
[11] 孙朝晖.中药肉苁蓉的药理活性研究进展[J].赤峰学院学报:自然科学版,2010,26(2):70-71.
[12] Peter JH,Hiroshi H.Anti-hepatotoxic activity of extracts and constituents of buddleja species[J].Planta Med,1989, 55(1):123.
[13] 朱启贵,方步武,竺稽能,等.牛血清白蛋白免疫性肝纤维化动物模型的研究[J].中华病理学杂志,1993,22(2):121.
[14] 程明亮,刘三都.肝纤维化的基础与临床[M].北京:人民卫生出版社,1996:146-147.
[15] 常晋芳.丹参酮ⅡA苦参素治疗肝纤维化临床疗效前后对照研究[J].中外妇儿健康,2011,19(7):32.
[16] 成海,刘平,胡义扬,等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术——中医药现代化,2007, 9(2):112-119.
[17] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中华肝脏病杂志,2006,14(11):161-163, 866-870.
[18] 木克热木·吐地买提,由淑萍,赵军,等.肉苁蓉苯乙醇苷类成分对BSA致大鼠肝纤维化影响的实验研究[J].新疆医科大学学报,2015,38(5):568-570.
[19] 王燕艳.肝硬化患者血清白蛋白、血清总胆红素与肝纤维化标志物的相关性研究[J].陕西医学杂志,2010,39(7):842-843.
[20] 魏金文,附江宁.血清前白蛋白、胆碱醋酶、胆汁酸联合检测对肝硬化分级临床价值评估[J].陕西医学杂志,2005, 34(12):1520-1522.
[21] 张斌.肝纤维化的发病机理研究进展[J].现代诊断与治疗,2004,15(6):355.
[22] 沈鼎明.肝纤维化的发生机制[J].中华肝脏病杂志,2002, 8(4):241.
[23] Bottinger EP,Miao J,Schiffer M,et al.Transforming growth factor beta signal transduction in the kidney[J]. Kidney Blood Press Res,1998,21(2/3/4):259-261.
[24] Rockey DC. Antifibrotic therapy in chronic liver disease[J]. Clin Gastroenterol Hepatol,2005,3(2):95-107.
[25] Parsons CJ,Bradford BU,Pan CQ,et al.Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats[J]. Hepatology,2004,40(5):1106-1115.

The effects of cistanche phenylethanoid glycosides on TGF-β1 expression of rats with hepatic fibrosis induced by BSA

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	ZHANG Shilei, YOU Shuping, ZHAO Jun, LIU Tao. Protective-effect-of Cistanche phenylethanoid glycoside liposomes on BSA induced liver fibrosis in rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 428-433.
[2]	ZHANG Shilei, YOU Shuping, MA Xiaoting, MA Long, ZHAO Jun, LIU tao. Effect of Cistanche phenylethanol glycoside liposomes on proliferation,apoptosis and cell cycle of HSC cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 289-294.
[3]	HU Qiong, YOU Shuping, LIU Tao, WANG Bo, LIU Xin, JIANG Yuandong. An investigation on the anti-liver cancer effect of cistanche [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 194-199.
[4]	YOU Shuping, ZHAO Jun, MA Long, ZHANG Shilei, LIU Tao. Effects of cistanche phenylethanoid glycosides, acteoside and echinacoside on inhibition of cell proliferation and inducation of apoptosis in rat hepatic stellate cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 13-17,22.
[5]	YOU Shuping, ZHAO Jun, MA Long, ZHANG Shilei, LIU Tao. Effect of phenylethanol glycosides on the TGF-β1/Smad signaling pathway in the rat HSC-T6 hepatic stellate cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(5): 372-376.